Vyome Holdings, Inc. (NASDAQ:HIND) Given Average Recommendation of “Hold” by Analysts

Vyome Holdings, Inc. (NASDAQ:HIND) has received an average rating of “Hold” from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $15.00.

A number of equities research analysts have recently issued reports on the stock. Zacks Research upgraded shares of Vyome to a “hold” rating in a report on Wednesday, May 6th. Weiss Ratings upgraded shares of Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Finally, Litchfield Hills Research assumed coverage on shares of Vyome in a report on Monday, May 4th. They set a “buy” rating on the stock.

Institutional Investors Weigh In On Vyome

An institutional investor recently bought a new position in Vyome stock. Geode Capital Management LLC purchased a new stake in shares of Vyome Holdings, Inc. (NASDAQ:HIND) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned 0.21% of Vyome at the end of the most recent reporting period. 22.06% of the stock is currently owned by institutional investors and hedge funds.

Vyome Price Performance

HIND stock opened at $2.16 on Tuesday. Vyome has a 12 month low of $1.75 and a 12 month high of $18.60. The firm has a market cap of $15.16 million, a PE ratio of -0.18 and a beta of 1.48. The firm has a 50 day simple moving average of $2.16 and a 200 day simple moving average of $2.96.

Vyome (NASDAQ:HIND) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter. Vyome had a negative net margin of 270.58% and a negative return on equity of 203.92%. The business had revenue of $0.03 million for the quarter. As a group, sell-side analysts expect that Vyome will post -0.6 earnings per share for the current year.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.